Skip to content
Home » News » Courts » UPDATE: What’s next for Rep. Collins district after resignation, guilty plea?

UPDATE: What’s next for Rep. Collins district after resignation, guilty plea?

Rep. Chris Collins resigns ahead of expected guilty plea

New York GOP Rep. Chris Collins has resigned his seat effective Monday, according to a Republican source, one day ahead of an expected guilty plea to federal insider trading charges.

The 69-year-old Collins, one of the first GOP lawmakers to back President Donald Trump before the 2016 election, is scheduled to make an appearance in federal court Tuesday in Manhattan. Collins will plead guilty to insider trading charges related to his investment in an Australian biotech firm, according to court documents and GOP sources.

Continue reading from

What happens to the New York 27th Congressional District seat?

With Rep. Chris Collins’ resignation and expected guilty plea, the question becomes: What will happen to the seat he held in Congress?

Much of if and when a special election will take place for the seat resides with Governor Andrew Cuomo.

After the death of Congresswoman Louise Slaughter in March 2018, a primary election was called, and then Governor Cuomo called a special election in November with a vote to fill the remainder of Slaughter’s term and a vote to fill the seat for the next term.

Continue reading from WHEC-TV

Collins expected to plead guilty to insider trading charges

Rep. Chris Collins is slated to plead guilty in connection to an insider trading case.

The Republican Congressman is scheduled to have a court hearing in Manhattan at 3 p.m. Tuesday. He originally pleaded not guilty and will plead guilty to at least one charge, according to the U.S. District Court’s Southern District of New York.

In August 2018, Collins was charged with insider trading and lying to the FBI, along with his son Cameron and Stephen Zarsky, the father of Cameron’s girlfriend. Collins is accused of using non-public information from an Australian biotech firm to tip off his son to sell stock in the firm ahead of a failed clinical trial for a drug that treated multiple sclerosis. Collins was serving as a board member at the time

Continue reading from WHAM-TV